Abstract: The disclosure provides a naphthylurea compound having a formula I. In the formula, m and n represent a number of CH2, and are an integer from 1 to 10; k and z represent a number of CH2, and are an integer from 0 to 6; and p represents a number of CH2, and is 1, 2 or 3; and X is O or S.

Abstract: The disclosure provides a naphthylurea compound having a formula I. R represents H, a C1-C5 straight-chain alkyl, a C1-C5 straight-chain alkyl with a halogen-substituted end or a 5-8-membered cycloalkyl; R1, R2, R3, R4, R5, R6, R7, R8, R9 at each occurrence represent H, F, Cl, Br, —CN, —CH3, —CF3, —OCH3, or —OCF3; R5 optionally represents phenyl, and M is H or —CH3; m represents a number of CH2, and is 0 or 1; n represents a number of CH2, and is 1, 2, 3, or 4; and p represents a number of CH2, and is 2; and X is O or S.

Abstract: The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

Abstract: The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

Abstract: The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

Abstract: The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

Abstract: The present invention identified a recombinant synthetic collagen containing a triple helical backbone protein produced in a prokaryotic expression system where the protein contains at least one ‘inserted’ biologically active sequence(s).

Abstract: The present invention identified a recombinant synthetic collagen containing a triple helical backbone protein produced in a prokaryotic expression system where the protein contains at least one ‘inserted’ biologically active sequence(s).